Nissan Wants to 'Enhance Performance' In Its EVs. So It's Turning to Formula E, for Some Reason
attempts to fix its financial outlook
. That future could include new
Nismo
models designed with the help of Nissan's Formula E team.
Tommaso Volpe, the head of Nissan's electric racing outfit, revealed the possibility to
Autocar
in a recent interview. He told the publication that the automaker is considering developing "prototypes" that can help Nismo "enhance the performance of electric cars." However, Nissan hasn't made any official decision.
Volpe added that the upcoming Gen4 Formula E cars, for 2026-2027, could provide the potential for transferring technology from electric race cars to future road-going products. The Gen4 cars will feature all-wheel drive with two electric motors producing around 800 horsepower, as per regulations written in collaboration with participating manufacturers, including
Nissan
.
That's more power than what the
Ariya Nismo
makes. The crossover is a twin-motor AWD electric vehicle, but it produces just 420 hp, and Nissan doesn't even sell it in America. More power and expertise from the racing side can't hurt future electric Nismos,
if people want them
.
Developing prototypes for future road-going Nismo models based on 800-hp race cars could result in something great, but such ideas are often watered down for the masses before production begins. However, as exciting as Nismo is for consumers and the brand, Nissan has other things to focus on first.
Nissan Isn't Doing Well:
Nissan Is Closing Its First Factory Built Outside of Japan
Nissan Takes 'Tough But Necessary Decision' to Close a Factory
Get the best news, reviews, columns, and more delivered straight to your inbox, daily.
back
Sign up
For more information, read our
Privacy Policy
and
Terms of Use
.
Source:
Autocar
Share this Story
X
Got a tip for us? Email:
tips@motor1.com
Join the conversation
(
)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
a minute ago
- CNBC
Asia markets set to open lower, tracking Wall Street losses
Asia-Pacific markets are expected to open lower, tracking losses on Wall Street as investors weighed weaker-than-expected economic data as well as fresh tariff comments from U.S. President Donald Trump. "We're going to be announcing [tariffs] on semiconductors and chips, which is a separate category, because we want them made in the United States," Trump said on Tuesday stateside, adding that he'll announce the new plan "within the next week or so." Happy Wednesday from Singapore. Asia markets are poised for a lower open. Australia's S&P/ASX 200 was set to start the day lower with futures tied to the benchmark at 8,739, compared with its last close of 8,770.4. Japan's benchmark Nikkei 225 was set to open higher, with the futures contract in Osaka last traded at 40,555 against the index's last close of 40,549.54. Futures for Hong Kong's Hang Seng Index stood at 24,812, pointing to a weaker open compared with the HSI's last close of 24,902.53. — Lee Ying Shan The three leading U.S. indexes finished lower Tuesday. The S&P 500 fell 0.49%, closing at 6,299.19, while the Nasdaq Composite slid 0.65% to end at 20,916.55. The Dow Jones Industrial Average moved 61.90 points lower, or 0.14%, to settle at 44,111.74. — Sean Conlon U.S. President Donald Trump speaks to reporters near Air Force One at the the Lehigh Valley International Airport on August 03, 2025 in Allentown, Pennsylvania. Anna Moneymaker | Getty Images President Donald Trump spoke with "Squawk Box" in a wide-ranging conversation. Here are some of the highlights: On semiconductors, Trump said his administration is going to announce new tariffs "within the next week or so." "We're going to be announcing on semiconductors and chips, which is a separate category, because we want them made in the United States," he said during the interview. When it comes to his planned pharmaceutical tariffs, Trump said that the levies could eventually reach up to 250%. That's the highest tariff rate he's threatened to date. The president also revealed in the interview that he's considering four candidates for future Federal Reserve chair, which does not include Treasury Secretary Scott Bessent. "Well, I love Scott, but he wants to stay where he is," Trump said. — Kevin Breuninger, Annika Kim Constantino, Jeff Cox, Sean Conlon
Yahoo
29 minutes ago
- Yahoo
George Kent (Malaysia) Berhad Full Year 2025 Earnings: EPS: RM0.009 (vs RM0.049 loss in FY 2024)
Explore George Kent (Malaysia) Berhad's Fair Values from the Community and select yours George Kent (Malaysia) Berhad (KLSE:GKENT) Full Year 2025 Results Key Financial Results Revenue: RM137.5m (up 2.3% from FY 2024). Net income: RM4.71m (up from RM25.8m loss in FY 2024). Profit margin: 3.4% (up from net loss in FY 2024). EPS: RM0.009 (up from RM0.049 loss in FY 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period George Kent (Malaysia) Berhad shares are down 4.2% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 4 warning signs for George Kent (Malaysia) Berhad (1 doesn't sit too well with us!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
3 Asian Stocks That May Be Priced Below Intrinsic Value In August 2025
As global markets grapple with renewed tariff tensions and economic uncertainties, Asian indices have also felt the impact, with some experiencing declines amid broader market volatility. In this environment, investors may find opportunities in stocks that appear to be priced below their intrinsic value, offering potential for growth despite the challenges. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Wuxi Zhenhua Auto PartsLtd (SHSE:605319) CN¥32.94 CN¥65.50 49.7% Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) CN¥112.65 CN¥223.99 49.7% Nanya Technology (TWSE:2408) NT$44.40 NT$87.23 49.1% Nan Ya Printed Circuit Board (TWSE:8046) NT$177.50 NT$351.52 49.5% Inspur Digital Enterprise Technology (SEHK:596) HK$10.40 HK$20.45 49.1% Insource (TSE:6200) ¥917.00 ¥1814.21 49.5% GEM (SZSE:002340) CN¥6.51 CN¥12.96 49.8% Finger (KOSDAQ:A163730) ₩13480.00 ₩26881.94 49.9% Faraday Technology (TWSE:3035) NT$158.00 NT$313.77 49.6% cottaLTD (TSE:3359) ¥441.00 ¥866.89 49.1% Click here to see the full list of 271 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Cosmax Overview: Cosmax, Inc. is engaged in the research, development, production, and manufacturing of cosmetic and health functional food products both in Korea and internationally, with a market cap of ₩2.88 trillion. Operations: The company generates revenue primarily from its Cosmetics Sector, which amounts to ₩2.23 billion. Estimated Discount To Fair Value: 43.4% Cosmax appears undervalued, trading at ₩253,500, significantly below its estimated fair value of ₩448,068.1. Despite a slower revenue growth forecast of 12.7% annually compared to the market's 7.1%, earnings are expected to grow significantly at 25.5% per year, outpacing the Korean market's 22%. However, debt coverage by operating cash flow remains a concern despite high future return on equity projections of 26.8%. Recent events focused on enhancing business understanding in Southeast Asia may provide further insights into financial positioning. Our earnings growth report unveils the potential for significant increases in Cosmax's future results. Click here and access our complete balance sheet health report to understand the dynamics of Cosmax. WEILONG Delicious Global Holdings Overview: WEILONG Delicious Global Holdings Ltd, with a market cap of HK$30.27 billion, produces and sells spicy snack food in the People's Republic of China and internationally. Operations: The company's revenue is primarily derived from three segments: Vegetable Products (CN¥3.37 billion), Seasoned Flour Products (CN¥2.67 billion), and Bean-Based and Other Products (CN¥228.69 million). Estimated Discount To Fair Value: 43.8% WEILONG Delicious Global Holdings is trading at HK$12.45, significantly below its estimated fair value of HK$22.15, suggesting undervaluation based on cash flows. Despite a revenue growth forecast of 15.2%, slower than 20% but above the Hong Kong market's 8.1%, earnings are set to grow at 17.24% annually, surpassing the market's 10.7%. However, significant insider selling and dividends not well covered by free cash flows pose potential concerns for investors. Our expertly prepared growth report on WEILONG Delicious Global Holdings implies its future financial outlook may be stronger than recent results. Take a closer look at WEILONG Delicious Global Holdings' balance sheet health here in our report. Xiangyu MedicalLtd Overview: Xiangyu Medical Co., Ltd focuses on the research, development, manufacturing, and marketing of rehabilitation and physiotherapy equipment, with a market cap of CN¥8.24 billion. Operations: The company's revenue segment is primarily derived from its Medical Devices division, generating CN¥760.48 million. Estimated Discount To Fair Value: 10.3% Xiangyu Medical Ltd., trading at CN¥53.43, is below its fair value estimate of CN¥59.57, presenting an undervaluation opportunity based on cash flows. With earnings poised to grow significantly at 32.39% annually, outpacing the Chinese market's 23.7%, it offers robust growth prospects despite a low forecasted return on equity of 9.4%. However, profit margins have declined from last year and recent share price volatility may concern investors. The growth report we've compiled suggests that Xiangyu MedicalLtd's future prospects could be on the up. Click here to discover the nuances of Xiangyu MedicalLtd with our detailed financial health report. Next Steps Investigate our full lineup of 271 Undervalued Asian Stocks Based On Cash Flows right here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Looking For Alternative Opportunities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A192820 SEHK:9985 and SHSE:688626. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
